The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...

Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

(Bloomberg) -- GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can lead ...

GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing a rare neurological disorder, Reuters writes.

Pfizer's complaint is that GSK and a Quebec, Canada-based subsidiary ID Biomedical are causing "commercial uncertainty" for its own RSV vaccine programme with the three patents, which Pfizer says ...